EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments

Yosuke Kasai iD, Takashi Ito iD, Toshihiko Masui, Kazuyuki Nagai, Takayuki Anazawa, Yoichiro Uchida, Takamichi Ishii, Koji Umeshita, Susumu Eguchi, Yuji Soejima, Hideki Ohdan, Etsuro Hatano

Journal of Gastroenterology · 2025

DOI: 10.1007/s00535-024-02166-z ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Yosuke Kasai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. Hauptthemen laut MEDLINE: Intestinal Neoplasms, Liver Neoplasms, Liver Transplantation, Neuroendocrine Tumors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Kyoto University Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastroenteropancreatic neuroendocrine tumors (NET) often metastasize to the liver. Although curative liver resection provides a favorable prognosis for patients with neuroendocrine liver metastasis (NELM), with a 5-year survival rate of 70–80%, recurrence is almost inevitable, mainly in the remnant liver. In Western countries, liver transplantation (LT) has been performed in patients with NELM, with the objective of complete removal of macro- and micro-NELMs. However, prognosis had been unsatisfactory, with 5-year overall survival and recurrence-free survival rates of approximately 50 and 30%, respectively. In 2007, the Milan criteria were proposed as indications for LT for NELM. The criteria included: (1) confirmed histology of NET-G1 or G2; (2) a primary tumor drained by the portal system and all extrahepatic diseases removed with curative resection before LT; (3) liver involvement ≤50%; (4) good response or stable disease for at least 6 months before LT; (5) age ≤ 55 years. A subsequent report demonstrated outstanding LT outcomes for NELM within the Milan criteria, with 5-year overall survival and recurrence rates of 97 and 13%, respectively. In Japan, living donor LT (LDLT) for NELM has been performed sporadically in only 16 patients by 2021 in Japan; however, no consensus has been reached on the indications or perioperative management of LDLT. This article presents the outcomes of these 16 patients who underwent LDLT in Japan and reviews the literature to clarify optimal indications and perioperative management of LDLT for NELM in the era of novel multimodal treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal NeoplasmsLiver NeoplasmsLiver TransplantationNeuroendocrine TumorsPancreatic NeoplasmsPatient SelectionStomach NeoplasmsHumansCombined Modality TherapyNeoplasm Recurrence, LocalPerioperative CareSurvival Rate

Stichwörter der Autor:innen

Living donor liver transplantationMultimodal treatmentNeuroendocrine liver metastasisPeptide receptor radionuclide therapy

Autor:innen und Institutionen

  • Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. itotaka@kuhp.kyoto-u.ac.jp.
  • Department of Surgery, Kurashiki Central Hospital, Okayama, Japan.
  • Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Osaka International Cancer Institute, Osaka, Japan.
  • Department of Surgery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

ORCID-Profile: Yosuke Kasai, Takashi Ito

Förderung

  • The Kyoto University Foundation

Zitieren

APA

Kasai, Y., Ito, T., Masui, T., Nagai, K., Anazawa, T., Uchida, Y., Ishii, T., Umeshita, K., Eguchi, S., Soejima, Y., Ohdan, H., & Hatano, E. (2025). Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02166-z

Vancouver

Kasai Y, Ito T, Masui T, Nagai K, Anazawa T, Uchida Y, et al. Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments. Journal of Gastroenterology. 2025. doi:10.1007/s00535-024-02166-z

BibTeX
@article{Kasai2025,
  author = {Kasai, Yosuke and Ito, Takashi and Masui, Toshihiko and Nagai, Kazuyuki and Anazawa, Takayuki and Uchida, Yoichiro and Ishii, Takamichi and Umeshita, Koji and Eguchi, Susumu and Soejima, Yuji and Ohdan, Hideki and Hatano, Etsuro},
  title = {Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments},
  journal = {Journal of Gastroenterology},
  year = {2025},
  doi = {10.1007/s00535-024-02166-z}
}
Kostenlos starten →